RE:Fourth Quarter Should be Busy! Is there anyone on the board that has experience working in Phama Access that can comment on the length of process to setup reimbursement in the USA? I have not heard if TH has an medical access team or single person or person at all? Was this position hired near the same time as the marketing manager? If TH has people on staff that work entirely on this, can we not expect this to be handled very quickly regardless of the holiday season?
"Right now, Bloomberg suggest the 1Q18 TH sales will be $25.4 million. I can easily see how they might have $15 million in Egrifta sales but getting $10.4 million in Ibalizumab sales in Q1 in order to meet those expectations could prove to be a challenge due to need to get reimbursement arrangements in place first, which will be complicated by the holiday period in the US just after approval."